ABSTRACT
INTRODUCTION
The maintenance, proliferation and differentiation of stem and progenitor cells are ultimately controlled at the level of gene expression, which is closely tied to the global and local epigenetic status in the cell. A paradigm for such epigenetic control of gene expression is shown by two well-established antagonistic histone modifications: H3K27 methylation, catalyzed by the Polycomb group complexes, and H3K4 methylation, mainly catalyzed by the Trithorax group complexes.
1 While H3K27 methylation is generally associated with gene repression, H3K4
methylation is prevalently associated with gene activation. 2, 3 Roles for Polycomb group complexes and H3K27 methylation have been extensively studied in both embryonic stem cells (ESCs) [4] [5] [6] and hematopoietic stem and progenitor cells (HSC and HPCs). [7] [8] [9] [10] [11] [12] [13] [14] [15] On the other hand, the functional roles for H3K4 methylation in the maintenance and differentiation of stem and progenitor cells remain largely unclear.
The SET1/MLL family complexes are the most notable H3K4 methyltransferases in mammals.
They are composed of either SET1A, SET1B, MLL1, MLL2, MLL3, or MLL4 as the catalytic subunit, and WDR5, RBBP5, ASH2L, and DPY30 as integral core subunits that are required for the full methylation activity of these complexes. 2, [16] [17] [18] [19] The functional roles of the SET1/MLL complexes are especially pertinent to the hematopoietic system, as MLL1 (MLL, Mixed Lineage Leukemia) is a common target of chromosomal translocations in human acute leukemias, [20] [21] [22] and other subunits of the complexes are extensively associated with diseases including blood cancers. 23, 24 The molecular mechanisms underlying MLL1-fusion-mediated leukemogenesis remain incompletely understood. [25] [26] [27] Mll1 is essential for normal hematopoiesis [28] [29] [30] [31] [32] and a wild type Mll1 allele is critical for MLL1-AF9-mediated leukemogenesis. 33 Although the H3K4 methylation activity of MLL1 was concluded in a recent report to be important for MLL1-AF9-mediated leukemogenesis, 34 it was later shown in another report to be dispensable for this process as well as normal hematopoiesis, 35 underscoring the complex relationship of the enzymatic activity and the protein's function. The lack of impact on global or gene-specific H3K4 methylation upon acute Mll1 deletion 35 makes it difficult to investigate the role of H3K4 methylation in hematopoiesis through Mll1 deletion. Hematopoietic studies on other SET1/MLL complex subunits are scarce, and have limited information on the involvement of the methylation activity, 36 thus leaving a major gap between chromatin regulation by H3K4 methylation and hematopoiesis.
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We have previously shown that the DPY30 subunit of the SET1/MLL complexes is important for facilitating genome-wide H3K4 methylation. 37 While dispensable for self-renewal of mouse ESCs, Dpy30 is crucial for induction of developmental genes and efficient differentiation of ESCs. 37 Whether DPY30 plays a similar role in the maintenance and differentiation of somatic stem and progenitor cells remains unknown. Here we sought to address a fundamental question regarding the role of H3K4 methylation in hematopoietic progenitor function by depleting DPY30
in various systems including human HPCs and zebrafish. freshly supplemented with stem cell factor (SCF; 100 ng/ml), Fms-like tyrosine kinase 3 (FLT-3;
Methods

Purification, culture, and infection of human CD34 + cells and leukemia cells
10 ng/ml), thrombopoietin (TPO; 100 ng/ml), interleukin-6 (IL-6; 20 ng/ml), and low density lipoprotein (LDL 40 ng/ml). The cytokines were purchased from PeproTech (New Jersey 38 were cultured in RPMI-1640 (Invitrogen) containing 10% fetal bovine serum (Invitrogen). TF-1 culture also contained 2 ng/ml GM-CSF.
pLKO.1-based lentiviral constructs expressing scramble control (Addgene plasmid 1864) and DPY30 shRNAs (Table S1) were from Addgene and OpenBiosystems, respectively. Viral particles were produced following the recommended protocols (Addgene) and concentrated when necessary. After 1-3 days of growth, CD34 + cells were infected with concentrated viruses in the presence of 8 µg/ml of polybrene (Sigma, Missouri). Two days after infection, puromycin (2 µg/ml) was added, and 3 more days later, cells were used for various assays including the liquid differentiation assays. Leukemia cells were infected with un-concentrated viruses with the same method, except that 8 µg/ml of protamine sulfate (Sigma) was used for infecting cells. BrdUTP incorporation and cell apoptosis were analyzed on the stably-infected cells using 
Gene expression and ChIP assays
Details of the gene expression and chromatin immunoprecipitation (ChIP) assays are provided in Supplemental Methods. The microarray data reported in this article have been deposited in the Gene Expression Omnibus database (accession number GSE59643).
Methylcellulose colony assays
Indicated numbers of stably-infected live CD34+ cells were plated in human methylcelluloseenriched medium (HSC005, R&D Systems, Minnesota) containing EPO (3 IU/ml), G-CSF (20 ng/ml), GM-CSF (20 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and SCF (50 ng/ml). Burst-forming units-erythroid (BFU-E), granulocyte colony-forming units (CFU-G), granulocyte-macrophage colony-forming units (CFU-GM), and granulocyte erythrocyte macrophage megakaryocyte colony-forming units (CFU-GEMM) were scored 14 days later. A total of 10,000 stably-infected live MLL1-fusion-mediated leukemia cells were plated in human methylcellulose base media (HSC002, R&D Systems) with no cytokines. After recovery of colonies from the first plating, 10,000 live cells were re-plated in the same medium. No antibiotics was contained in the methylcellulose media.
Differentiation assays in liquid culture
Puromycin-selected CD34 + cells were cultured in medium that supports either erythroid (IMDM, 20% BIT 9500, SCF 100 ng/ml, EPO 1 units/ml) or myelomonocytic differentiation (IMDM, 20% BIT 9500, SCF 100 ng/ml, FLT-3 ligand 10 ng/ml, IL-3 20 ng/ml, IL-6 20 ng/ml, GM-CSF 20 ng/ml, G-CSF 20 ng/ml). All differentiation media contained 2 µg/ml puromycin. At indicated days after culture under differentiation conditions, cells were stained with Glycophorin A-PE (BD 561051) and CD71-APC (BD 561940) for erythroid differentiation and with CD34-APC (BD 560940) and CD11b-PE (BD 561001) for myeloid differentiation. Flow cytometry was performed using LSRFortessa Cell Analyzer (BD Biosciences) and the data were analyzed by FlowJo (Tree Star, Ashland, OR).
Zebrafish work
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From Zebrafish (Danio rerio, strain AB) were maintained under standard conditions in the UAB zebrafish core facility in accordance with the UAB policy on animal care and use. Anti-sense morpholino oligonucleotides (MOs) were purchased from Gene Tools, LLC (Philomath, OR).
Indicated dose of MO at 0.5-1nl was microinjected into embryos at the 1-2 cell stage. dpy30 mRNA was injected alone or co-injected with MO at 100pg/nl (50-100pg/embryo). Details of zebrafish work are in Supplemental Methods.
Results
DPY30 directly promotes ex vivo proliferation of primary hematopoietic progenitors.
To investigate the role of DPY30 in human HPCs, we used two different shRNA-expressing lentiviruses to stably and efficiently knock down (KD) DPY30 expression ( Figure 1A ) in primary human CD34 + cells purified from mobilized peripheral blood, which are enriched for HPCs. We confirmed that global H3K4 methylation was reduced by DPY30 KD (Fig 1B) . We then analyzed the effect of DPY30 KD on global gene expression in these cells by microarray analyses. As shown in Table S3 , 284 genes were down-regulated by both shRNAs to below ¾, and 62 genes to below 2/3, of the levels in control cells. Gene ontology analysis revealed that genes involved in DNA replication and cell cycle regulation were mostly overrepresented among these genes ( Figures 1E and S2C) . We confirmed the microarray results for selected genes including MYC, CDCA7, MCM2, MCM3, and MCM4, using quantitative PCR (q-PCR) ( Figure 1F ). As shown by chromatin immunoprecipitation (ChIP) assays, the transcription start sites of these tested genes, but not that of a negative control gene Figure   S5A and B). Cell proliferation was not found to be significantly reduced by DPY30 KD during the myelomonocytic differentiation ( Figure S6 ).
As cell identity is ultimately determined by its gene expression profile, we performed microarray analyses to characterize the effect of DPY30 KD on gene expression after myelomonocytic differentiation. Our results indicate that the genes whose post-differentiation expression was reduced over 2 fold by DPY30 KD (235 genes, listed in Table S4 ) were significantly enriched for defense response, antigen processing and presentation, and inflammatory response ( Figure   2C ), hallmark functions for differentiated myelomonocytic cells. Such enrichment was specific, as it was not found for genes whose expression was enhanced by DPY30 KD (data not shown).
By RT-qPCR, we further showed that while these genes were efficiently induced in control cells after culture under myelomonocytic differentiation condition, their induction was greatly impaired in the DPY30-KD cells ( Figures 2D and S5C ). Taken together, these results demonstrate an important role for DPY30 in the myelomonocytic differentiation of human HPCs.
DPY30 KD promotes erythroid maturation in HPCs and erythroleukemia cells
We next examined the effect of DPY30 KD on erythroid differentiation of human HPCs using a differentiation assay in liquid culture containing erythropoietin (EPO). We first showed that 
DPY30 ortholog is required for embryonic hematopoiesis in zebrafish
We next examined a role of DPY30 in a live vertebrate model, zebrafish, which has a highly conserved DPY30 ortholog, dpy30 ( Figure 4A ). Two different translation-blocking morpholino oligonucleotides (MOs) were designed to target the zebrafish dpy30 transcript at the 5' (MO-1) or 3' (MO-2) to the translation start codon ( Figure 4B ). Injection of 3.5-7.0 ng (designated as 1x dose) of a non-targeting control MO generated no detectable abnormalities compared to uninjected embryos ( Figure S10A and Video 1), and we therefore used un-injected embryos as control for most of the later experiments. Injection of either of the two dpy30 MOs at lower doses consistently resulted in severe developmental abnormalities. The most obvious phenotypes were cardiac edema (not shown) and reduction or abrogation of blood circulation, as demonstrated by the time-lapse video microscopy ( Figures 4C, 4D , S10B, and S11A, and Video 2). O-dianisidine staining for hemoglobin showed a severely reduced number of red blood cells in most of the morphant embryos ( Figures 4E, 4F , S10C, and S11B). The abnormalities persisted as late as 5 days after fertilization (data not shown), suggesting that they were not merely due to a delay in development.
The phenotypes we observed are very different from the commonly observed non-specific morpholino toxicity. 43 To further exclude the possibility of off-target effects, we synthesized zebrafish dpy30 mRNA that lacked the MO-1 target sequence. While injection of the dpy30 mRNA alone resulted in a slightly elevated mortality rates, its co-injection together with dpy30
MO-1 partially but significantly rescued the severe defects in blood circulation (Figures 4D and S10B, and Video 3) and red blood cell production ( Figure 4F and S10C). In addition to erythroid development, we also examined lymphoid development by in situ hybridization assays for rag1, a gene specific and required for lymphopoiesis. In contrast to the normal expression of rag1 in the bilateral thymic lobes, rag1 signal was greatly reduced or abolished in the dpy30 morphant fish 5 days after fertilization ( Figures 4H and S12) , indicating a defect in lymphoid development.
Therefore, our results collectively indicate that dpy30 is crucial for embryonic hematopoiesis in zebrafish. Consistent with a conserved dpy30 function in facilitating H3K4 methylation, we found a clear defect in H3K4 methylation in the dpy30 morphant fish extract ( Figure 4G ). To examine effects on HSC/HPC, we performed in situ hybridization for several hematopoiesis markers including tal1, gata1a and fli1a, some of which are functionally critical for early hematopoiesis and/or HSC formation. 44 Surprisingly, despite the defective erythropoiesis and lymphopoiesis, expression of all of these markers at 30 hpf was enhanced in the morphant fish ( Figure 4I and S13), suggesting an abnormal accumulation of HSCs and/or early HPCs in the embryos with lowered levels of dpy30 and global H3K4 methylation. and S15A). DPY30 KD also impaired the clonogenicity of both RS4; 11 and KOPN-8 cells in serial plating, although the effects in the second plating were less prominent ( Figure 5D ). We found that the DPY30 KD efficiency was attenuated by the end of the second plating (comparing Figure 5A with S15B), suggesting that the leukemia cells with low DPY30 level were outcompeted by cells with relatively high DPY30 level in forming colonies in the methylcellulose.
DPY30 KD impairs the growth of MLL1-fusion-mediated leukemia cell lines
These results suggest a detrimental effect of losing DPY30 for the self-renewal ability of the leukemia stem cells contained in at least some of these MLL1-fusion-mediated leukemia cell lines. Toward a mechanistic understanding of the effect of DPY30 KD in these leukemia cells, we confirmed that global H3K4 methylation was reduced by DPY30 KD in MOLM-13 cells ( Figure 5E ), and found that, similar to the effect in HPCs, genes involved in cell proliferation were down-regulated by DPY30 KD in MOLM-13 cells ( Figure 5F ).
Discussion
As the major H3K4 methylation enzymes in mammals, the SET1/MLL complexes are considered potential pharmacological targets in epigenetic therapeutics. However, a major barrier in targeting these complexes for hematological diseases is our poor understanding of the role for their H3K4 methylation activity in physiological and pathological hematopoiesis. The direct and important function of Dpy30 for efficient genome-wide H3K4 methylation 37 allows the effective functional interrogation of H3K4 methylation in hematopoietic cells by DPY30 depletion. Our work here has shown an important role of DPY30 in the ex vivo proliferation and differentiation of human HPCs as well as zebrafish hematopoiesis. It is possible that either one or more of the SET1/MLL family members are responsible for the H3K4 methylation activity involved in hematopoiesis. As discussed in our previous work 37 and elsewhere, 50 we cannot formally exclude the possibility that DPY30 may regulate hematopoiesis through functions other than facilitating H3K4 methylation.
Our results strongly suggest a role of DPY30 in direct control of human HPC proliferation through regulation of genes critically involved in DNA replication and cell cycle progression.
These findings are consistent with a role of DPY30 in promoting proliferation and preventing senescence in fibroblast cells. 51 We have also shown that DPY30 is crucial for the growth of Furthermore, no significant overrepresentation of major function groups was found for genes significantly affected by DPY30 depletion in mouse ESCs. 37 These results suggest that the functionally critical targets of DPY30 and its associated H3K4 methylation are highly cell-type dependent, and should be separately characterized in different cells.
The effect of DPY30 KD on CFU-G and CFU-GM colony formation is consistent with that on the (E) Global gene expression was examined by microarray, followed by gene ontology analysis on the genes down-regulated by both shRNAs to below ¾ of the levels in control cells (listed in Table S3 ).
(F) Expression of selected genes from microarray assays was examined by RT-qPCR against POLR2A. Two different sets of primers were used for MYC. Averages ± SD from 4 independent biological repeats are plotted. P<0.05 (Student's t-test) between control and either DPY30
shRNAs for all genes.
(G) ChIP assays for total H3, H3K4me3, and DPY30 binding at the transcription start sites of a negative control gene (OR2J3) and those genes examined in (F) in human CD34 + cells.
Averages ± SD from triplicate assays are plotted.
Figure 2. DPY30 KD impaired myelomonocytic differentiation of human HPCs.
Control and DPY30-KD human CD34 + cells were cultured with appropriate cytokine conditions that permit myelomonocytic differentiation.
(A) Cell morphology at day 11 under such culture condition.
(B) Percentage of myelomonocytic population (CD34 -CD11b + ) at day 14 in the differentiation assays were quantified. Averages ± SD from 3 biological repeats (infections) are plotted. **
P<0.01 (Student's t test).
(C) RNAs from control and DPY30-KD (by sh#2) cells at day 9 during myelomonocytic differentiation were subject to microarray assays, followed by gene ontology analysis for the genes down-regulated over 2 fold by DPY30 KD (listed in Table S4 ).
(D) RNAs from control and DPY30-KD (by sh#2 and #5) cells at day 0 (d0) and day 14 (d14) during myelomonocytic differentiation were subject to RT-qPCR for selected genes highlighted in Table S4 . Averages ± SD from 2 independent biological repeats are plotted. 
